윤유석 (성균관대학교) | 상위피인용논문 > 한빛사

상위피인용논문

조회162

성균관대학교

CV File 115 kb

Biomaterials, Volume 34, Issue 27 , September 2013, Pages 6444-6453 | https://doi.org/10.1016/j.biomaterials.2013.05.018 Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer

Insoo Kim ^a, Hyeong Jun Byeon ^a, Tae Hyung Kim ^a, Eun Seong Lee ^b, Kyung Taek Oh ^c, Beom Soo Shin ^d, Kang Choon Lee ^a, Yu Seok Youn ^a,*

^aSchool of Pharmacy, Sungkyunkwan University, 300 Cheoncheon-dong, Jangan-gu, Suwon 440-746, Republic of Korea

^bDivision of Biotechnology, The Catholic University of Korea, 43-1 Yeokgok 2-dong, Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea

^cCollege of Pharmacy, Chung-Ang University, 221 Heukseok dong, Dongjak-gu, Seoul 155-756, Republic of Korea

^dCollege of Pharmacy, Catholic University of Daegu, 330 Geumrak 1-ri, Hayang Eup, Gyeongsan si, Gyeongbuk 712-702, Republic of Korea

^*Corresponding author: correspondence to Yu Seok Youn

Abstract

Inhalable highly porous large PLGA microparticles with incorporated doxorubicin and surface-attached with TRAIL (TRAIL/Dox PLGA MP) were fabricated using a w/o/w double emulsification method using ammonium bicarbonate as a gas-foaming agent for the treatment of lung cancer. The TRAIL/Dox PLGA MP produced were highly porous and 11.5 ± 0.4 μm in diameter, and the loading efficiencies of Dox and TRAIL were 86.5 ± 6.5% and 91.8 ± 2.4%, respectively. TRAIL and doxorubicin were gradually released by TRAIL/Dox PLGA over 7 days, and pulmonary administration resulted in the deposition of TRAIL/Dox PLGA MP in mouse lungs, and they remained in situ for up to a week. The anti-tumor efficacy of pulmonary administered TRAIL/Dox PLGA MP was evaluated in a BALB/c nu/nu mice mouse model of H226 cell metastasis. Tumors in H226-implanted mice treated with TRAIL/Dox PLGA MP were markedly smaller and fewer in number than mice treated with TRAIL or Dox PLGA MP alone. Furthermore, this improved performance was found to be due to the synergistic apoptotic effects of the two drugs. We believe that TRAIL/Dox PLGA MP offer a promise of a sustained-release, long-acting, inhalable anti-lung cancer agent. Furthermore, the synergism observed between TRAIL and doxorubicin suggests that the doxorubicin dosage could be substantially reduced and its side effects minimized.

논문정보

형식Research article
게재일2013년 09월 (BRIC 등록일 2024-07-26)
연구진국내 연구진
분야 의약학 > 약학
피인용횟수120회 이상 인용된 논문

댓글 작성 로그인

CV 열람하기

연락처 보기